LENZ Therapeutics (LENZ) Price & Analysis

Compare

268 Followers

LENZ Stock Chart & Stats

Day’s Range― - ―

52-Week Range$16.54 - $50.40

Previous CloseN/A

Volume24.39K

Average Volume (3M)487.28K

Market Cap

$1.32B

Enterprise Value$614.42M

Total Cash (Recent Filing)$209.52M

Total Debt (Recent Filing)$1.05M

Price to Earnings (P/E)―

Beta1.05

Next Earnings

Nov 05, 2025

EPS Estimate

-0.69

Last Dividend Ex-Date

Mar 22, 2024

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.53

Shares Outstanding28,522,097

10 Day Avg. Volume753,190

30 Day Avg. Volume487,280

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.47

Enterprise Value/Revenue121.28

Enterprise Value/Gross Profit123.20

Enterprise Value/Ebitda-9.93

Forecast

1Y Price Target

$52.00

Price Target Upside34.06% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

Bulls Say, Bears Say

Bulls Say

Competitive AdvantageVizz is the only eye drop approved that is not based on pilocarpine but on aceclidine, improving near vision without impacting distant vision.

Product LaunchThe commercial availability of Vizz marks Lenz's transition into a commercial-stage company with a best-in-class profile for the large, untapped market of presbyopia.

Regulatory ApprovalLENZ has announced FDA approval of lead product LNZ-100, now branded VIZZ, and notably a week earlier than expected, an upside surprise.

Bears Say

Future Marketing PlansLenz plans to start direct-to-consumer marketing in the first quarter of 2026 to increase consumer demand.

Launch MetricsEarly launch metrics may face interpretability issues due to limitations around reporting of e-pharmacies.

Product PricingThe cash-pay pricing appears competitive, set at $79 for a one-month supply.

LENZ Therapeutics News

Lenz Therapeutics price target raised to $67 from $51 at Piper Sandler

Piper Sandler raised the firm’s price target on Lenz Therapeutics (LENZ) to $67 from $51 and keeps an...

3d ago

LENZ

Short Report: TeraWulf short interest at record high despite stock strength

Welcome to this week’s installment of “The Short Interest Report” – The Fly’s weekly recap of short interest...

7d ago

RKT

Lenz Therapeutics announces U.S. commercial availability of VIZZ

LENZ Therapeutics (LENZ) announced VIZZ 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of...

13d ago

LENZ

Lenz Therapeutics announces availability of VIZZ in U.S.

Lenz Therapeutics (LENZ) announced VIZZ 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of...

13d ago

LENZ

LENZ Therapeutics Raises $80M Through Stock Sale

LENZ Therapeutics ( ($LENZ) ) has shared an announcement. On October 7, 2025, LENZ Therapeutics sold 1,748,634 shares...

4d ago

LENZ

LENZ Therapeutics: Buy Rating Affirmed Amid Successful Early Launch of Vizz and Promising Market Potential

William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on LENZ stock, giving a Buy rating...

13d ago

LENZ

LENZ Therapeutics Launches FDA-Approved Presbyopia Eye Drop

LENZ Therapeutics ( ($LENZ) ) just unveiled an announcement. On September 30, 2025, LENZ Therapeutics announced the availability...

13d ago

LENZ

Strong Buy Recommendation for LENZ Therapeutics: Early Approval and Strategic Launch of VIZZ Eye Drops

LENZ Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst on August 1. Analyst Marc...

2M ago

LENZ

Lenz Therapeutics price target raised to $53 from $44 at BofA

BofA analyst Jason Gerberry raised the firm’s price target on Lenz Therapeutics (LENZ) to $53 from $44 and...

2M ago

LENZ

Lenz Therapeutics price target raised to $56 from $48 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Lenz Therapeutics (LENZ) to $56 from $48 and keeps a...

2M ago

LENZ

Buy Rating for LENZ Therapeutics: Vizz’s Early FDA Approval and Market Differentiation Drive Growth Potential

LENZ Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason Gerberry from...

2M ago

LENZ

Lenz Therapeutics price target raised to $52 from $49 at Citi

Citi raised the firm’s price target on Lenz Therapeutics (LENZ) to $52 from $49 and keeps a Buy...

2M ago

LENZ

LENZ Therapeutics Gains FDA Approval for VIZZ Eye Drop

LENZ Therapeutics ( ($LENZ) ) has shared an announcement. On July 31, 2025, LENZ Therapeutics announced the FDA...

2M ago

LENZ

Lenz Therapeutics announces FDA approval of Vizz eye drop

Lenz Therapeutics (LENZ) announced the FDA approved Vizz 1.44%, the first and only FDA-approved aceclidine-based eye drop for...

2M ago

LENZ

LENZ FAQ

What was LENZ Therapeutics’s price range in the past 12 months?

LENZ Therapeutics lowest stock price was $16.54 and its highest was $50.40 in the past 12 months.

What is LENZ Therapeutics’s market cap?

LENZ Therapeutics’s market cap is $1.32B.

When is LENZ Therapeutics’s upcoming earnings report date?

LENZ Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 23 days.

How were LENZ Therapeutics’s earnings last quarter?

LENZ Therapeutics released its earnings results on Jul 30, 2025. The company reported -$0.53 earnings per share for the quarter, beating the consensus estimate of -$0.61 by $0.08.

Is LENZ Therapeutics overvalued?

According to Wall Street analysts LENZ Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does LENZ Therapeutics pay dividends?

LENZ Therapeutics pays a Notavailable dividend of $7.21 which represents an annual dividend yield of N/A. See more information on LENZ Therapeutics dividends here

What is LENZ Therapeutics’s EPS estimate?

LENZ Therapeutics’s EPS estimate is -0.69.

How many shares outstanding does LENZ Therapeutics have?

LENZ Therapeutics has 28,522,097 shares outstanding.

What happened to LENZ Therapeutics’s price movement after its last earnings report?

LENZ Therapeutics reported an EPS of -$0.53 in its last earnings report, beating expectations of -$0.61. Following the earnings report the stock price went down -2.873%.

Which hedge fund is a major shareholder of LENZ Therapeutics?

Currently, no hedge funds are holding shares in LENZ

LENZ Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-26.25%

Trailing 12-Months

Asset Growth

7.25%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

LENZ Therapeutics

LENZ Therapeutics (LENZ) is a biopharmaceutical company focused on developing innovative treatments for eye diseases. The company operates in the healthcare sector, specifically targeting ophthalmology, with a primary emphasis on developing therapies for presbyopia and other vision-related disorders. LENZ leverages cutting-edge science and technology to create novel therapeutics that address unmet medical needs in the field of eye care.

LENZ Therapeutics (LENZ) Earnings & Revenues

Historic Earnings Reports

LENZ Stock 12 Month Forecast

Average Price Target

$52.00

▲(34.06% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"20":"$20","32":"$32","44":"$44","56":"$56","68":"$68"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$67.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":52,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$52.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$36.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[20,32,44,56,68],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.05,50.43076923076923,51.81153846153846,53.19230769230769,54.57307692307692,55.95384615384615,57.33461538461538,58.715384615384615,60.09615384615385,61.47692307692307,62.857692307692304,64.23846153846154,65.61923076923077,{"y":67,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.05,49.276923076923076,49.503846153846155,49.730769230769226,49.957692307692305,50.184615384615384,50.41153846153846,50.638461538461534,50.86538461538461,51.09230769230769,51.31923076923077,51.54615384615384,51.77307692307692,{"y":52,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.05,48.04615384615384,47.04230769230769,46.03846153846153,45.034615384615385,44.03076923076923,43.026923076923076,42.02307692307692,41.01923076923077,40.01538461538462,39.011538461538464,38.00769230769231,37.003846153846155,{"y":36,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.39,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.8,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.93,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.87,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.53,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.83,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.01,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.88,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.16,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.05,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.25,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.05,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >